Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > NanoKTN Helps UK Start-Up Reach International Audience and Profitability

Abstract:
The NanoKTN is pleased to announce that one of its members, NanoSight, has recently secured its 250th sale and has reached profitability for the first time since the company was established in 2005. NanoSight's CEO Jeremy Warren believes support from the NanoKTN has had significant, commercial impact on the success of the business.

NanoKTN Helps UK Start-Up Reach International Audience and Profitability

UK | Posted on January 6th, 2011

NanoSight's technology has been installed worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever, together with many leading universities and research institutes.

UK-based NanoSight has developed a revolutionary technique to view nanoparticles down to the size of several millionths of a millimetre. This opens previously unimagined possibilities such as for the development of viral vaccines and drug delivery systems, both of which require a great deal of precision. The NanoSight technique measures on a particle-by-particle basis and so generates high-resolution particle-size distributions, allowing an accurate and precise measurement of virus or drug delivery particle numbers and sizes. This has clear implications for the manufacturing processes as well as helping to optimize the product yield.

From their start, NanoSight has attended NanoKTN events as both a speaker and exhibitor, using them as a means of securing business contacts within industry and academia. By talking to industry professionals within the field and by meeting with academics from leading research institutions and universities, NanoSight has been able to increase its new business prospects as well as providing the company with a platform to deliver information about the benefits of its technology directly to its target audience.

"There is no doubt that the NanoKTN events have been invaluable to our business, as has the dedicated commitment and support which has been provided to us by the NanoKTN staff," explains Warren. "They have provided us with vital access to the nanotechnology market, both in the UK and abroad, helping us to develop our market understanding. Through conferences and focus groups, the NanoKTN has made the market more coherent, bringing academia and commercial players together, developing a solid MNT network."

With continued support from the NanoKTN's Theme Managers, NanoSight has been able to develop contact with key market professionals and generate new sales internationally. NanoSight has grown rapidly and has secured its position in the market as a leading manufacturer of unique nanoparticle characterization technology, more than 90% of sales being outside the UK.

CEO Warren adds, "I would strongly recommend companies joining the NanoKTN. Membership is essential to those wanting to learn more about the key players in the nanotechnology market and to help to build their company profile. Their events have provided us with valuable networking opportunities and are crucially important to ensure the growth of the UK nanotechnology market."

####

For more information, please click here

Contacts:
General KTN enquiries

T: +44 (0)1740 625 790

Copyright © NanoKTN

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Tools

New material to make next generation of electronics faster and more efficient With the increase of new technology and artificial intelligence, the demand for efficient and powerful semiconductors continues to grow November 8th, 2024

Turning up the signal November 8th, 2024

Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024

Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Nanobiotechnology

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024

New-Contracts/Sales/Customers

Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center: New Advanced Imaging Center Powered by Two MuVi and LCS SPIM Microscopes March 25th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Veeco Announces Aledia Order of 300mm MOCVD Equipment for microLED Displays: Propel™ Platform First 300mm System with EFEM Designed for Advanced Display Applications October 20th, 2020

GREENWAVES TECHNOLOGIES Announces Next Generation GAP9 Hearables Platform Using GLOBALFOUNDRIES 22FDX Solution October 16th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project